Diagnostic value of plasma TNF-? and IL-8 levels in patients with prostate cancer [Serum TNF-? ve IL-8 düzeylerinin prostat kanserli hastalardaki tanisal degeri]
Introduction: In this study, we aimed to evaluate TNF-? and IL-8 levels in patient with prostate cancer as diagnostic tools additional to PSA. Materials and Methods: In this current study, we included a total of 37 patients who were planned to undergo prostate biopsies in Department of Urology of Zonguldak Karaelmas University due to having high PSA levels between January and December 2005. Two samples of serum each containing 100 µL plasma were collected from each patient in order to measure TNF-? and IL-8 levels by using Immulite® IL8 and Immulite® TNF-? immunometric assays and results were given in pg/mL unit. TNF-? and IL-8 levels were compared in groups of BPH and prostate cancer. Additionally, Gleason score and those parameters were compared within prostate cancer group. Results: IL-8 levels were between 5.0 pg/mL to 46.2 pg/ml and mean IL-8 level was 12.1 pg/ml; TNF-? levels were between 4.0 pg/ml to 10 pg /mL and mean TNF-? level was 5.64 pg/ml in prostate cancer group (n=20). IL-8 levels were between 5.0 pg/ml to 27.4 pg/ml and mean IL-8 level was 9.094 pg/ml; TNF-? levels were between 4.0 pg/ml to 9 pg /mL and mean TNF-? level was 5.46 pg/ml in BPH group (n = 17) (p>0.05). There was no statistical corelation detected between Gleason score and those parameters. Conclusion: There were not any significant statistical difference in TNF-? and IL-8 levels between patients with BPH and prostate cancer. IL-8 and TNF-? do not seem to diagnostic value in patients with prostate cancer. However, the role of TNF-? and IL-8 in prostate cancer etiology and their roles in diagnosing prostate cancer and prognosis of prostate cancer should be investigated in larger series
